Neoadjuvant Pembrolizumab Shows Promise in Early-Stage dMMR/MSI-High Colorectal Cancer

Recent clinical trial results indicate that neoadjuvant pembrolizumab may offer a significant treatment advancement for patients with high-risk, early-stage deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer. The findings, presented at major oncology conferences, suggest the immunotherapy approach can lead to high rates of pathological complete response without observed relapses in the short-to-medium term.

Understanding the Trial Design and Patient Population

The NEOPRISM-CRC study is a multicenter phase 2 trial specifically designed to evaluate the safety and effectiveness of neoadjuvant pembrolizumab in patients with operable, high-risk stage II or stage III dMMR/MSI-H colorectal cancer. A key feature of the trial’s design was the stratification of treatment based on tumor mutation burden (TMB), an emerging biomarker thought to predict response to immunotherapy in this cancer subtype.

Participants were divided into two groups according to their TMB status. Patients with tumors classified as TMB-high or TMB-medium received three cycles of pembrolizumab administered at a dose of 200 mg every three weeks. Those with TMB-low tumors received a single cycle of the same regimen. In both groups, surgical intervention was scheduled to occur within four to six weeks following the completion of the neoadjuvant treatment.

Primary and Secondary Endpoints

The primary endpoint of the NEOPRISM-CRC trial was the pathological complete response (pCR) rate, defined as the absence of viable tumor cells in the resected specimen following neoadjuvant therapy. Secondary endpoints included critical long-term outcomes such as 3-year relapse-free survival and overall survival, alongside assessments of safety, health-related quality of life, and exploratory translational research aimed at identifying novel predictive biomarkers in blood, tumor tissue, and the microbiome.

To ensure statistical validity, the trial was powered to detect a pCR rate of at least 33% in the TMB-high/medium cohort, with a minimum clinically intriguing threshold set at 10%. Success was predefined as achieving a pCR in at least five patients within this subgroup.

Key Efficacy Findings

Upon analysis of the intent-to-treat population, which included all 32 enrolled patients, the pathological complete response rate was 53%. In the evaluable tumor population—a subset where tissue was adequately assessable—the pCR rate was slightly higher at 58%. When focusing specifically on the patients with TMB-high or TMB-medium tumors, the pCR rate was 55% in the intent-to-treat group and 59% in the evaluable group. These results surpassed the trial’s predefined success threshold.

Notably, across the reported follow-up period, which extended to approximately three years for some patients, no relapses were observed among those who achieved a pathological complete response. This observation suggests a potential correlation between early pathological response and sustained disease control, although longer-term data will be necessary to confirm the durability of this benefit.

Safety and Translational Research Components

Beyond efficacy, the trial placed significant emphasis on characterizing the safety profile of neoadjuvant pembrolizumab in this localized setting. Comprehensive monitoring of adverse events was conducted throughout the treatment and postoperative phases. The study incorporated extensive correlative science components, collecting serial blood, tumor, and microbiome samples to investigate potential biomarkers that could further refine patient selection or predict response to PD-1 blockade in early-stage dMMR/MSI-H colorectal cancer.

Context and Implications

Deficient mismatch repair and high microsatellite instability represent a distinct molecular subtype of colorectal cancer, accounting for approximately 15% of cases. While these tumors tend to be more responsive to immune checkpoint inhibitors in the metastatic setting, their management in early-stage disease has traditionally relied on surgery followed by adjuvant chemotherapy, with variable outcomes. The NEOPRISM-CRC results contribute to a growing body of evidence supporting the use of immunotherapy earlier in the treatment continuum, potentially offering a path to spare some patients from the toxicity of conventional chemotherapy while achieving excellent disease control.

As research continues, ongoing and future studies will aim to define the optimal duration of neoadjuvant therapy, identify which patients might safely avoid surgery altogether based on exceptional response, and determine the long-term impact on survival and quality of life. The integration of biomarkers like TMB, as explored in this trial, may prove crucial in personalizing this approach.

The NEOPRISM-CRC trial underscores the potential of biomarker-driven immunotherapy to transform the management of genetically defined colorectal cancer subsets, moving toward more precise and effective treatment strategies.